We found that linc00969 was significantly increased in trastuzumab-resistant patients blood samples, both in 44 early-stage HER-2+ BC patients and 64 metastatic HER-2+ BC patients (Fig. 2C–E). This evidence concerns the gene ERBB2 and breast cancer.